Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed.The ...
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
Coming four years after her last record, Forever is Lilly Hiatt’s strongest blend yet of alt-rock guitars with Americana ...
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...
Compared to Lilly’s Zepbound (tirzepatide), the once-daily experimental drug would be simpler to produce.